Global Precision Medicine Market Research Report – Forecast to 2022

Global Precision Medicine Market Research Report – Forecast to 2022

ID: MRFR/HC/0420-CRR | March, 2017 | Region: Global | 313 pages | Cooked Research Reports

Global Precision Medicine market Information, By Ecosystem (pharma & biotech companies, diagnostic tool companies, healthcare IT/ big data companies, clinical laboratories), By Sub-markets (companion diagnostics, biomarker-based test, targeted therapeutics, pharmacogenomics, molecular diagnostics, others), By Therapeutics (cancer/oncology, cardiovascular disease, central nervous system, infectious diseases, others) - Forecast to 2022


Market Synopsis of Global Precision Medicine Market:
Market Scenario:
Precision medicine refers to medicines developed as per an individual’s genetic profile that helps as a guide for the prevention, diagnosis and treatment of diseases. The global precision medicine market was valued at $38.92 billion in 2015, and is expected to reach $88.64 billion by 2022. Thus the market is expected to perform a growth at a CAGR of 12.48% from 2015 to 2022.

The major market driving factor for precision medicine are patient’s involvement in personal healthcare, integration of wireless technologies with portable healthcare devices, and increase in genetic diseases (due to mutation, UV rays) among others.

The market constraints include potential threat to personal data, high diagnostic cost as a barrier, potential risk of hardware or software failure, stringent regulations and standards, lack of awareness about the possible applications of precision medicine, reimbursement policies and regulatory framework, limited knowledge about the application of test and techniques, lack of research and evidences creating hindrances in its application.


Study Objectives Global Precision Medicine Market:



  • To provide detailed analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the global precision medicine market

  • To provide insights about factors affecting the market growth

  • To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.

  • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.

  • To provide country level analysis of the market with respect to the current market size and future prospective

  • To provide country level analysis of the market for segments by ecosystem (pharma & biotech companies, diagnostic tool companies, healthcare it/ big data companies, clinical laboratories), by sub-markets (companion diagnostics, biomarker-based test, targeted therapeutics, pharmacogenomics, molecular diagnostics, others), by therapeutics (cancer/oncology, cardiovascular disease, central nervous system, infectious diseases, others)

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments globally.


Global Precision Medicine Market, by Region 2015 & 2022 (USD million)


 Global Precision Medicine Market, by Region 2015 & 2022 (USD million) 


Intended Audience:



  • Global Precision Medicine manufacturers

  • Global Precision Medicine suppliers

  • Research and Development Laboratories

  • Market Research and Consulting Service Providers


Key Finding:



  • The global precision medicine market is expected to reach USD 88.64 billion by 2022.

  • By ecosystem diagnostic tool companies holds the largest market share of precision medicine market and is expected to reach USD 27.56 billion by 2022.

  • By sub-market, company diagnostics holds the largest market share of precision medicine market and is expected to reach USD 21.32 billion by 2022.


Key Players for Global Precision Medicine Market:
Abbott Laboratories, Almac Group, Ltd., Asuragen, Inc., Biomérieux Sa, Cepheid Inc., Cetics Healthcare Technologies Gmbh, Ge Healthcare, Glaxosmithkline Plc, Johnson & Johnson, Laboratory Corporation Of America Holdings, Medtronic, Novartis, Pfizer Inc., Qiagen, Biobase Gmbh, Quest Diagnostics Inc, Randox Laboratories Ltd., Sanofi Pharma, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Ab-Biotics Sa, Caris Life Sciences, Healthcore, Inc., Ibm, Innventis, Intel Corporation, Molecular Health Gmbh, Precision For Medicine


Segments:
Global Precision Medicine market has been segmented on the basis of ecosystem, sub-market, therapeutics and region.


Regional Analysis of Global Precision Medicine Market:
Globally North America is the largest market for global precision medicine. Europe is the second-largest market for global precision medicine. The near future market for precision medicine will be dominated by the developed regions with developing regions providing a supporting role only. However the developing regions market particularly Asia Pacific will be the fastest growing and is likely to be the key to the future.

The report for Global Precision Medicine Market of Market Research Future comprises extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

License

Single User Enterprise User (Buy Premium Reports Chapterwise)
TABLE OF CONTENTS

1.1 Scope Of The Study

1.2 Precision Medicine: Report Coverage

1.3 Research Methodology

1.3.1 Research Methodology For The Global Market Study

1.3.1.1 Geographical Analysis

1.3.1.2 Demand Side & Supply Side Analysis

1.3.1.3 Data Synthesis And Bridging

1.3.2 Global Precision Medicine: Research Methodology

1.3.3 Key Data Point Sources

1.3.3.1 Data Points Taken From Secondary Sources

1.3.3.2 Data Points Taken From Primary Sources

1.4 Report Description

3.1 Introduction

3.2 Market Timeline

3.3 Key Participants, Strategies & Developments

3.3.1 Government Agencies

3.3.2 Academic Institutions

3.3.3 Device & Service Providers

3.4 Key Market Strategies And Developments

3.4.1 Introduction

3.4.2 Partnerships, Agreements, And Collaborations

3.4.3 Mergers & Acquisitions

3.4.4 Product Development And Launch

3.4.5 Business Expansion/Contracts

3.4.6 Patents, Approvals And Certifications

3.4.7 Others (Events & Recognitions)

4.1 Introduction

4.2 Market Drivers

4.2.1 Patients Involvement In Personal Healthcare

4.2.2 Technologies Driving The Market (E.G. Next-Generation Sequencing Technologies, Ultra-High Throughput Sequencing)

4.2.3 Increase In Genetic Diseases

4.2.4 Potential For More Targeted Therapies

4.2.5 Integration Of Big Data Healthcare Companies With Pharma & Biotech Companies

4.3 Market Challenges

4.3.1 Potential Threat To Personal Data

4.3.2 High Diagnostic Cost As A Barrier

4.3.3 Potential Risk Of Hardware Or Software Failure

4.3.4 Stringent Regulations And Standards

4.3.5 Lack Of Awareness About The Possible Applications Of Precision Medicine

4.3.6 Reimbursement Policies And Regulatory Framework

4.3.7 Limited Knowledge About The Application Of Test And Techniques

4.3.8 Lack Of Research And Evidences Creating Hindrances In Its Application

4.4 Market Opportunities

4.4.1 Introduction Of Precision Medicine Solutions In Developing Economies

4.4.2 Downsizing The Cost Of Genome Sequencing To Three Digits

5.1 Value Chain Analysis

5.1.1 Device Manufacturer & Drug Producers

5.1.2 Healthcare Providers

5.1.3 Healthcare Its Or Big Data Companies

5.1.4 Regulators

5.1.5 Third Party Payers

5.1.6 Patients

5.2 Porter Five Force Analysis

5.2.1 Bargaining Power Of Buyer (Patient)

5.2.2 Bargaining Power Of Supplier

5.2.3 Threat From Substitute

5.2.4 Threat From A New Entrant

5.2.5 Intensity Of Competitive Rivalry

6.1 Introduction

6.1.1 Regulatory Bodies

6.1.1.1 Food And Drug Administration (Fda)

6.1.1.2 Medicines And Healthcare Products Regulatory Agency (Mhra)

6.1.1.3 Therapeutic Goods Administration (Tga)-Australia

6.1.1.4 Conformité Européenne (Ce)

6.1.2 Consortiums

6.1.3 Alliances/Associations

7.1 Introduction

7.1.1 Market Statistics

7.2 Pharmaceuticals And Biotechnology Companies

7.2.1 Key Market Trends, Developments And Participants

7.2.1.1 Market Trends

7.2.1.2 Market Developments

7.2.1.3 Key Participants

7.3 Diagnostic Companies

7.3.1 Key Market Trends, Developments And Participants

7.3.1.1 Market Trends

7.3.1.2 Market Developments

7.3.1.3 Key Participants

7.4 Healthcare It Specialists/ Big Data Companies

7.4.1 Key Market Trends, Developments And Participants

7.4.1.1 Market Trends

7.4.1.2 Market Developments

7.4.1.3 Key Participants

7.5 Clinical Laboratories

7.5.1 Key Market Trends, Developments And Participants

7.5.1.1 Regulatory Bodies And Compliances

7.5.1.2 Market Trends

7.5.1.3 Key Participants

8.1 Introduction

8.1.1 Market Statistics

8.2 Companion Diagnostics

8.3 Biomarker-Based Test

8.3.1 Role Of Biobanking Into Biomarker

8.3.2 Key Participants

8.4 Targeted Therapeutics

8.4.1 Key Participants

8.5 Pharmacogenomics (Pgx)

8.5.1 Key Market Trends, Developments And Participants

8.5.1.1 Market Trends

8.5.1.2 Market Developments

8.5.1.3 Key Participants

8.6 Molecular Diagnostics

8.7 Others

8.7.1 Next-Generation Sequencing

8.7.2 Consumer Genomics

8.7.2.1 Key Participants

8.7.3 3d Printing

8.7.4 Prosthetics Market

8.7.5 Human Tissues Market

9.1 Introduction

9.1.1 Market Statistics

9.2 Cancer/Oncology

9.2.1 Market Statistics

9.2.2 Types Of Cancer

9.2.3 Drugs & Tests

9.2.4 Key Market Trends, Developments & Participants

9.2.4.1 Market Trends

9.2.4.2 Market Developments

9.2.4.3 Key Participants

9.3 Cardiovascular Disease (Cvd)

9.3.1 Market Statistics

9.3.2 Drugs & Tests

9.3.3 Market Trends & Market Developments

9.3.3.1 Market Trend

9.3.3.2 Market Developments

9.3.3.3 Key Participants

9.4 Central Nervous System

9.4.1 Market Statistics

9.4.2 Neurological

9.4.2.1 Neurological Drugs & Tests

9.4.3 Psychiatric Disorders

9.4.3.1 Psychiatric Disorder Drugs & Tests

9.4.4 Market Tends & Market Developments

9.4.4.1 Market Trends

9.4.4.2 Key Developments

9.4.4.3 Key Participants

9.5 Infectious Diseases

9.5.1 Market Statistics

9.5.2 Infectious Diseases Drugs & Tests

9.5.3 Market Developments & Participants

9.5.3.1 Key Developments

9.5.3.2 Key Participants

9.6 Others

9.6.1 Market Statistics

9.6.2 Market Trends, Developments & Participants

9.6.2.1 Market Trends

9.6.2.2 Key Developments

9.6.2.3 Key Participants

10.1 Introduction

10.1.1 Market Statistics

10.2 The Americas

10.2.1 North America

10.2.1.1 The U.S.

10.2.1.2 Canada

10.2.1.3 Others

10.2.1.4 Key Market Trends, Developments And Participants

10.2.1.5 Regulations And Compliances

10.2.1.6 Market Trends

10.2.1.7 Market Developments

10.2.1.8 Key Participants

10.2.2 South America

10.2.2.1 Key Market Trends, Developments And Participants

10.2.2.2 Regulations And Compliances

10.2.2.3 Market Trends

10.2.2.4 Key Participants

10.3 Europe

10.3.1 Key Market Trends, Developments And Participants

10.3.1.1 Regulations And Compliances

10.3.1.2 Market Developments

10.3.1.3 Key Participants

10.4 Asia-Pacific (Apac)

10.4.1 Key Market Trends, Developments And Participants

10.4.1.1 Market Developments

10.4.1.2 Key Participants

10.5 Rest Of The World/Midde East & Africa (Mea)

10.5.1 Africa

10.5.1.1 Middle East

10.5.2 Key Market Developments And Participants

10.5.2.1 Market Developments

10.5.2.2 Key Participants

11.1 Abbott Laboratories

11.1.1 Overview

11.1.2 Financials

11.1.2.1 Overall Financials

11.1.2.2 Financials By Segment

11.1.2.3 Financials By Region

11.1.2.4 Key Developments

11.1.3 Swot Analysis

11.2 Almac Group, Ltd.

11.2.1 Overview

11.2.2 Financials

11.2.3 Key Developments

11.2.4 Swot Analysis

11.3 Asuragen, Inc.

11.3.1 Overview

11.3.2 Financials

11.3.3 Key Developments

11.3.4 Swot Analysis

11.4 Biomérieux Sa

11.4.1 Overview

11.4.2 Financials

11.4.2.1 Overall Financials

11.4.2.2 Financials By Region

11.4.2.3 Financials By Segment

11.4.3 Key Developments

11.4.4 Swot Analysis

11.5 Cepheid Inc.

11.5.1 Overview

11.5.2 Financials

11.5.2.1 Overall Financials

11.5.2.2 Net Revenue By Segment

11.5.2.3 Net Revenue By Region

11.5.3 Key Developments

11.5.4 Swot Analysis

11.6 Cetics Healthcare Technologies Gmbh

11.6.1 Overview

11.6.2 Financials

11.6.3 Key Developments

11.6.4 Swot Analysis

11.7 Ge Healthcare

11.7.1 Overview

11.7.2 Financials

11.7.2.1 Overall Financials

11.7.2.2 Net Revenue By Segment

11.7.2.3 Financial Summary

11.7.3 Key Developments

11.8 Glaxosmithkline Plc (Gsk)

11.8.1 Overview

11.8.2 Financials

11.8.2.1 Overall Financials

11.8.2.2 Financials By Segment

11.8.2.3 Financials By Region

11.8.2.4 Financials By Therapeutics

11.9 Intomics A/S

11.9.1 Overview

11.9.2 Financials

11.9.3 Key Developments

11.9.4 Swot Analysis

11.10 Johnson & Johnson

11.10.1 Overview

11.10.2 Financials

11.10.2.1 Overall Financials

11.10.2.2 Net Revenue By Segment

11.10.2.3 Net Revenue By Region

11.10.3 Key Developments

11.11 Laboratory Corporation Of America Holdings

11.11.1 Overview

11.11.2 Financials

11.11.2.1 Overall Financials

11.11.2.2 Financials By Segment

11.11.3 Key Developments

11.11.4 Swot Analysis

11.12 Medtronic

11.12.1 Overview

11.12.2 Financials

11.12.2.1 Overall Financials

11.12.3 Key Developments

11.13 Novartis

11.13.1 Overview

11.13.2 Financials

11.13.2.1 Overall Financials

11.13.2.2 Financials By Region

11.13.2.3 Financials By Segment

11.14 Pfizer Inc.

11.14.1 Overview

11.14.2 Financials

11.14.2.1 Overall Financials

11.14.2.2 Net Revenue By Segment

11.14.2.3 Net Revenue By Region

11.14.3 Key Developments

11.14.4 Swot Analysis

11.15 Qiagen

11.15.1 Overview

11.16 Biobase Gmbh (Subsidiary)

11.16.1 Overview

11.16.2 Financials

11.16.2.1 Overall Financials

11.16.3 Key Developments (Biobase)

11.17 Quest Diagnostics Inc

11.17.1 Overview

11.17.2 Financials

11.17.2.1 Overall Financials

11.17.2.2 Net Revenue By Segment

11.17.3 Key Developments

11.17.4 Swot Analysis

11.18 Randox Laboratories Ltd.

11.18.1 Overview

11.18.2 Financials

11.18.3 Key Developments

11.18.4 Swot Analysis

11.19 Roche Holding Ag-Br

11.19.1 Overview

11.19.2 Financials

11.19.2.1 Overall Financials

11.19.2.2 Net Revenue By Segment

11.19.3 Key Developments

11.19.4 Swot Analysis

11.20 Sanofi Pharma

11.20.1 Overview

11.20.2 Financials

11.20.2.1 Overall Financials

11.20.2.2 Net Revenue By Segment

11.21 Takeda Pharmaceutical Company Limited

11.21.1 Overview

11.21.2 Financials

11.21.2.1 Overall Financials

11.21.3 Key Developments

11.21.4 Swot Analysis

11.22 Teva Pharmaceutical Industries Ltd.

11.22.1 Overview

11.22.2 Financials

11.22.2.1 Overall Financials

11.22.2.2 Net Revenue By Segment

11.22.2.3 Net Revenue By Segment

11.22.3 Key Developments

11.22.4 Swot Analysis

11.23 Ab-Biotics Sa

11.23.1 Overview

11.24 Caris Life Sciences

11.24.1 Overview

11.25 Healthcore, Inc.

11.25.1 Overview

11.26 Ibm

11.26.1 Overview

11.27 Innventis

11.27.1 Overview

11.28 Intel Corporation

11.28.1 Overview

11.29 Molecular Health Gmbh

11.29.1 Overview

11.30 Precision For Medicine

11.30.1 Overview

Table 1 Leading Companies In The Precision Medicine Market 37
Table 2 Downsizing Cost Of Genome Sequencing 74
Table 3 Factors Impacting The Buyer’s Bargaining Power 80
Table 4 Factors Impacting The Supplier’s Bargaining Power 81
Table 5 Factors Impacting The Threat From Substitute 82
Table 6 Factors Impacting The Threat From New Entrant 83
Table 7 Factors Impacting The Degree Of Competition 84
Table 8 Regulatory Bodies In Precision Medicine Market 87
Table 9 Consortiums In Precision Medicine Market 93
Table 10 Alliances/Associationsin Precision Medicine Market 94
Table 11 Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Billion) 97
Table 12 Pharma & Biotech: Global Precision Medicine Market Value, By Sub-Market Types, 2014-2022 ($Billion) 100
Table 13 Pharma & Biotech: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($Billion) 101
Table 14 Pharma & Biotech: Global Precision Medicine Market Value, By Geography, 2014-2022 ($Billion) 102
Table 15 Key Developments In Pharma & Biotech Companies(2015) 105
Table 16 Diagnostic Tools: Global Precision Medicine Market Value, By Sub-Market Types, 2014-2022 ($Billion) 107
Table 17 Diagnostic Tools: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($Billion) 108
Table 18 Diagnostic Tools: Global Precision Medicine Market Value, By Geography, 2014-2022 ($Billion) 109
Table 19 Key Developments In Diagnostic Companies(2015) 112
Table 20 Healthcare Its/Big Data: Global Precision Medicine Market Value, By Sub-Market Types, 2014-2022 ($Billion) 113
Table 21 Healthcare Its/Big Data: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($Billion) 114
Table 22 Healthcare Its/Big Data: Global Precision Medicine Market Value, By Geography, 2014-2022 ($Billion) 115
Table 23 Key Developments In Healthcare It/Big Data Companies(2015) 120
Table 24 Clinical Laboratories: Global Precision Medicine Market Value, By Sub-Market Types, 2014-2022 ($Billion) 122
Table 25 Clinical Laboratories: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($Billion) 123
Table 26 Clinical Laboratories: Global Precision Medicine Market Value, By Geography, 2014-2022 ($Billion) 124
Table 27 Global Precision Medicine Market Value, By Sub-Market Types, 2014-2022 ($Billion) 129
Table 28 Companion Diagnostics: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Million) 131
Table 29 Companion Diagnostics: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($Million) 132
Table 30 List Of Approved Companion Diagnostic Devices 133
Table 31 Biomarker: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Million) 135
Table 32 Biomarker: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($Million) 136
Table 33 List Of Biobanks 138
Table 34 Examples Of Biobanking Initiatives Across Selected Oecd Countries 139
Table 35 Targeted Therapeutics: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Million) 142
Table 36 Targeted Therapeutics: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($Million) 143
Table 37 Pharmacogenomics: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Million) 145
Table 38 Pharmacogenomics: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($Million) 146
Table 39 Molecular Diagnostics: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Million) 152
Table 40 Molecular Diagnostics: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($Million) 153
Table 41 Other Sub-Markets: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Million) 157
Table 42 Other Sub-Markets: Global Precision Medicine Market Value, By Therapeutic Application, 2014-2022 ($Million) 158
Table 43 Global Precision Medicine Market Value, By Therapeutic Applications, 2014-2022 ($Billion) 163
Table 44 Cancer: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Billion) 165
Table 45 Cancer: Global Precision Medicine Market Value, By Sub-Market Types, 2014-2022 ($Billion) 166
Table 46 Cancer: Global Precision Medicine Market Value, By Geography, 2014-2022 ($Billion) 167
Table 47 Precision Medicine Drugs And Relevant Genes: Oncology 170
Table 48 Precision Medicine Genetic Tests With Respect To Oncology 171
Table 49 Key Developments (2013-2015) 172
Table 50 Cvd: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Billion) 176
Table 51 Cvd: Global Precision Medicine Market Value, By Sub-Market Types, 2014-2022 ($Billion) 177
Table 52 Cvd: Global Precision Medicine Market Value, By Geography, 2014-2022 ($Million) 178
Table 53 Precision Medicine Drugs And Relevant Genes: Cardiovascular 179
Table 54 Precision Medicine Genetic Tests With Respect To Cardiovascular 180
Table 55 Key Developments (2014-2015) 181
Table 56 Cns: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Million) 182
Table 57 Cns: Global Precision Medicine Market Value, By Sub-Market Types, 2014-2022 ($Million) 183
Table 58 Cns: Global Precision Medicine Market Value, By Geography, 2014-2022 ($Million) 184
Table 59 Precision Medicine Drugs And Relevant Genes: Neurology 185
Table 60 Precision Medicine Drugs And Relevantgenes: Psychiatric Disorders 186
Table 61 Precision Medicine Genetic Tests With Respect To Psychiatric Disorders 187
Table 62 Psychiatric Disorders: Key Developments (2014-2015) 188
Table 63 Infectious Disease: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Million) 189
Table 64 Infectious Disease: Global Precision Medicine Market Value, By Sub-Market Types, 2014-2022 ($Million) 190
Table 65 Infectious Disease: Global Precision Medicine Market Value, By Geography, 2014-2022 ($Million) 191
Table 66 Precision Medicine Drugs And Relevant Genes: Infectious Diseases 192
Table 67 Other Therapeutics: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Million) 195
Table 68 Other Therapeutics: Global Precision Medicine Market Value, By Sub-Market Types, 2014-2022 ($Million) 196
Table 69 Other Therapeutics: Global Precision Medicine Market Value, By Geography, 2014-2022 ($Million) 197
Table 70 Precision Medicine Drugs And Relevant Genes: Other Diseases 198
Table 71 Precision Medicine Genetic Tests With Respect To Other Diseases 199
Table 72 Global Precision Medicine Market Value, By Geography, 2014-2022 ($Billion) 203
Table 73 Americas: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Billion) 204
Table 74 Americas: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Billion) 205
Table 75 Americas: Global Precision Medicine Market Value, By Therapeutic Applications, 2014-2022 ($Billion) 206
Table 76 Europe: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Billion) 213
Table 77 Europe: Global Precision Medicine Market Value, By Therapeutic Applications, 2014-2022 ($Billion) 214
Table 78 Apac: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Billion) 219
Table 79 Apac: Global Precision Medicine Market Value, By Therapeutic Applications, 2014-2022 ($Million) 220
Table 80 Row: Global Precision Medicine Market Value, By Ecosystem Players, 2014-2022 ($Million) 224
Table 81 Row: Global Precision Medicine Market Value, By Therapeutic Applications, 2014-2022 ($Million) 225

Figure 1 Precision Medicine Market Study 27
Figure 2 Research Methodology 29
Figure 3 Different Phases Of Research Methodology For The Global Market 30
Figure 4 Precision Medicine Market: Research Methodology 32
Figure 5 Global Precision Medicine Market Share, By Ecosystem, 2014-2022 ($Billion) 38
Figure 6 Global Precision Medicine Market Size, By Sub-Market Type, 2014 – 2022 (Billion) 39
Figure 7 Global Precision Medicine Market Size, By Therpeutic Application, 2014 – 2022 (Billion) 40
Figure 8 Global Precision Medicine Market Size, By Geography, 2014 – 2022 ($Billion) 41
Figure 9 Timeline Of Precision Medicine 43
Figure 10 Precision Medicine: Benefits 45
Figure 11 Examples: Applied Areas Of Precision Medicine 46
Figure 12 Elements Of Precision Medicine Technology 47
Figure 13 Different Type Of Data Used By Big Data Companies 48
Figure 14 Precision Medicine : Areas Of Interest 49
Figure 15 Precision Medicine: Partnerships, Agreements, And Collaborations (2015) 53
Figure 16 Precision Medicine : Mergers & Acquisitions( 2015) 55
Figure 17 Precision Medicine: Key Product Launch & Developments (2015) 57
Figure 18 Precision Medicine: Key Business Expansions & Contracts (2015) 58
Figure 19 Precision Medicine : Key Patents/ Approvals ( 2015) 59
Figure 20 Precision Medicine: Events & Recognition (2015) 60
Figure 21 Market Drivers And Challenges 61
Figure 22 Benefits Of Precision Medicine To Patients 63
Figure 23 Major Barriers Caused By Regulation And Standards 69
Figure 24 Flow Chart Of Precision Medicine 76
Figure 25 Precision Medicine Market: Porter Five Force Analysis 79
Figure 26 Roles And Responsibilities Of Healthcare Policy Makers 86
Figure 27 Role Of Fda In Precision Medicine 90
Figure 28 Classification Of Medical Devices 91
Figure 29 Global Precision Medicine Market By Ecosystem Players 98
Figure 30 Role Of Pharmaceuticals And Biotech Companies 103
Figure 31 Challenges Faced By Pharma & Biotech Companies 104
Figure 32 Diagnostic Tests Benefits For Stakeholders 110
Figure 33 Challenges Faced By Diagnostic Companies 111
Figure 34 Benefits Of Big Data 116
Figure 35 Transformation Of Medicine 117
Figure 36 Basic Ingredients Provided By Big Data For Precision Medicine 118
Figure 37 Challenges Faced By Big Data Companies 119
Figure 38 Oecd Recommendations On The Governance Of Clinical Trials 126
Figure 39 Types Of Precision Medicine Sub-Market 130
Figure 40 Benefits Of Companion Diagnostics 133
Figure 41 Function Of Biomarkers 137
Figure 42 Biobanks Services 141
Figure 43 Development In Pgx 147
Figure 44 Model Systems Used In Pgx 148
Figure 45 Challenges Of Pgx Studies 149
Figure 46 Figure Title Missing 154
Figure 47 Molecular Diagnostics: Application 155
Figure 48 Molecular Diagnostics: Benefits 156
Figure 49 Global Precision Medicine Market: By Therapeutics 164
Figure 50 Target Scope Of Precision Medicine By Cancer Types 169
Figure 51 Global Precision Medicine Market Classification, By Geography 202
Figure 52 Key Drivers For Precision Medicine: North America 207
Figure 53 Objectives Of The Precision Medicine Initiative 209
Figure 54 Apac: Market Challenges 221
Figure 55 Abbott: Overall Financials ($Billion), 2012-2014 228
Figure 56 Abbott: Net Revenue By Segments ($Billion), 2012-2014 228
Figure 57 Abbott: Net Revenue By Region, 2012-2014 ($Billion) 229
Figure 58 Abbott: Swot Analysis 231
Figure 59 Almac: Swot Analysis 234
Figure 60 Asuragen: Swot Analysis 237
Figure 61 Biomerieux: Overall Financials ($Million), 2012-2014 239
Figure 62 Biomerieux: Net Revenue By Region, 2014 239
Figure 63 Biomerieux: Net Revenue By Segment, 2014 240
Figure 64 Biomerieux: Swot Analysis 242
Figure 65 Cepheid: Overall Financials, 2012-2014 ($Million) 244
Figure 66 Cepheid: Net Revenue, By Segments, 2012-2014 ($Million) 245
Figure 67 Cepheid: Net Revenue, By Region, 2012-2014 ($Million) 245
Figure 68 Cepheid: Swot Analysis 247
Figure 69 Cetics Healthcare: Swot Analysis 250
Figure 70 Ge Corporation: Overall Financials, 2012-2014 ($Billion) 252
Figure 71 Ge Corporation: Net Revenue, By Segments, 2012-2014 ($Million) 253
Figure 72 Ge Corporation: Healthcare Segment, 2014 253
Figure 73 Gsk: Overall Financials, 2012-2014 ($Billion) 257
Figure 74 Gsk: Net Revenue By Segment, 2014 ($Billion) 257
Figure 75 Gsk: Net Revenue By Region, 2014 ($Billion) 258
Figure 76 Gsk: Net Revenue By Therapeutics, 2014 ($Billion) 258
Figure 77 Intomics: Swot Analysis 260
Figure 78 J&J: Overall Financials, 2012 - 2014 ($Billion) 262
Figure 79 J&J: Net Revenue By Segment, 2012 - 2014 ($Million) 262
Figure 80 J&J: Net Revenue By Region, 2012 - 2014 ($Million) 263
Figure 81 Labcorp: Overall Financials ($Million), 2012-2014 265
Figure 82 Net Revenue By Segments, 2012-2014 ($Million) 266
Figure 83 Labcorp: Swot Analysis 268
Figure 84 Medtronic: Overall Financials, 2012 - 2014 ($Million) 270
Figure 85 Novartis: Overall Financials, 2012 - 2014 ($Billion) 273
Figure 86 Novartis: Net Revenue By Region, 2014 ($Billion) 274
Figure 87 Novartis: Net Revenue By Segment, 2014 ($Billion) 274
Figure 88 Pfizer: Overall Financials, 2012 – 2014 ($Billion) 276
Figure 89 Pfizer: Net Revenue, By Segment, 2012-2014 ($Million) 276
Figure 90 Pfizer: Net Revenue, By Region, 2012-2014 ($Billion) 277
Figure 91 Pfizer: Swot Analysis 279
Figure 92 Qiagen: Overall Financials ($Million), 2012-2014 282
Figure 93 Qiagen: Net Revenue By Region ($Million), 2014 282
Figure 94 Qiagen: Net Revenue By Segment, 2014 283
Figure 95 Quest: Overall Financials, 2012 - 2014 ($Million) 285
Figure 96 Quest: Net Revenue, By Segment, 2012 - 2014 ($Million) 286
Figure 97 Quest: Swot Analysis 288
Figure 98 Randox: Swot Analysis 291
Figure 99 Roche: Overall Financials, 2012-2014 ($Billion) 293
Figure 100 Roche: Net Revenue, By Segments, 2012-2014 ($Billion) 293
Figure 101 Roche: Swot Analysis 295
Figure 102 Sanofi Pharma: Overall Financials, 2012-2014($Billion) 297
Figure 103 Sanofi Pharma: Net Revenue, By Segments, 2012-2014 ($Bilion) 297
Figure 104 Takeda: Overall Financials, 2012-2014 ($Billion) 299
Figure 105 Takeda: Swot Analysis 301
Figure 106 Teva: Overall Financials, 2012 – 2014 ($Billion) 303
Figure 107 Teva: Net Revenue Share, By Segment (2014) 303
Figure 108 Teva: Net Revenue Share, By Region (2014) 304
Figure 109 Teva: Swot Analysis 307